-
October 13, 2026Investor Relations (IR) Meeting
-
October 08, 2026Material Facts Report (Decision to Acquire Own Convertible Bonds Before Maturity)
-
October 02, 2026[Correction] Semi-Annual Report (2026.06)
-
September 18, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
September 17, 2026Investor Relations (IR) Meeting
-
September 14, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Approval)
(Phase 1/2 Clinical Trial of VRN110755) -
September 10, 2026[Correction] Report on Grant of Stock Options
-
September 09, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
September 09, 2026Material Business Matters Related to Investment Decisions (Voluntary Withdrawal of IND, etc.)
(Phase 1/2 Clinical Trial of VRN110755) -
August 31, 2026Report on Large Holdings of Shares, etc. (General)
-
August 28, 2026Report on Large Holdings of Shares, etc. (General)
-
August 21, 2026Investor Relations (IR) Meeting
-
August 18, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Approval)
(Phase 1/2 Clinical Trial of VRN110755) -
August 14, 2026Semi-Annual Report (2026.06)
-
August 07, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
July 31, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Approval)
(Phase 1/2 Clinical Trial of VRN110755) -
July 30, 2026[Attachment Correction] Material Facts Report (Designation of Call Option Exerciser for Convertible Bonds)
-
July 08, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
July 06, 2026Investor Relations (IR) Meeting
-
July 03, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
July 03, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
July 03, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
July 03, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
July 03, 2026Report on Large Holdings of Shares, etc. (General)
-
June 25, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
June 24, 2026[Correction] Material Facts Report (Decision to Acquire Own Convertible Bonds Before Maturity)
-
June 23, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
June 23, 2026Investor Relations (IR) Meeting
-
June 22, 2026Material Facts Report (Decision to Acquire Own Convertible Bonds Before Maturity)
-
June 22, 2026Report on Large Holdings of Shares, etc. (General)
-
June 22, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
June 10, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
June 08, 2026Report on Large Holdings of Shares, etc. (General)
-
June 08, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
June 08, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
June 02, 2026Investor Relations (IR) Meeting
-
May 27, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Approval)
(Phase 1/2 Clinical Trial of VRN110755) -
May 27, 2026Report on Large Holdings of Shares, etc. (General)
-
May 26, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
May 15, 2026Quarterly Report (2026.03)
-
May 13, 2026Investor Relations (IR) Meeting
-
May 08, 2026Material Facts Report (Designation of Call Option Exerciser for Convertible Bonds)
-
April 15, 2026Report on Large Holdings of Shares, etc. (General)
-
April 15, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
April 15, 2026Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
April 03, 2026Report on Large Holdings of Shares, etc. (General)
-
March 30, 2026Report on Appointment, Dismissal, or Mid-Term Resignation of Outside Directors
-
March 30, 2026Results of Annual General Meeting of Shareholders
-
March 27, 2026[Correction] Material Business Matters Related to Investment Decisions (Decision on IND Application, etc.)
(Phase 1 IND Approval for VRN101099) -
March 26, 2026Material Business Matters Related to Investment Decisions (IND Amendment Approval)
(Phase 1/2 Clinical Trial of VRN110755) -
March 20, 2026Annual Report (2025.12)
-
March 20, 2026Submission of Audit Report
-
March 13, 2026Reference Documents for Proxy Solicitation
-
March 13, 2026Notice of Convening General Meeting of Shareholders
-
March 12, 2026[Correction] Report on Reasons for Holding General Meeting of Shareholders on a Peak Date
-
March 12, 2026Resolution to Convene General Meeting of Shareholders
-
March 11, 2026Investor Relations (IR) Meeting
-
March 05, 2026Report on Large Holdings of Shares, etc. (General)
-
February 26, 2026Investor Relations (IR) Meeting
-
February 24, 2026Report on Large Holdings of Shares, etc. (General)
-
February 13, 2026Change of 30% or More in Revenue or Profit/Loss Structure (15% for Large Corporations)
-
February 06, 2026Material Business Matters Related to Investment Decisions (IND Amendment Application)
(Phase 1/2 Clinical Trial of VRN110755) -
February 04, 2026[Correction] Material Business Matters Related to Investment Decisions (Decision on IND Application, etc.)
(Phase 1 IND Approval for VRN110755) -
January 15, 2026[Correction] Material Business Matters Related to Investment Decisions (IND Application)
(A Phase 1 Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Efficacy of VRN101099 in Patients with HER2-Driven Solid Tumors) -
December 30, 2025Report on Large Holdings of Shares, etc. (General)
-
December 30, 2025Report on Results of Treasury Share Disposal
-
December 29, 2025Material Facts Report (Decision to Dispose of Treasury Shares)
-
December 18, 2025Report on Large Holdings of Shares, etc. (General)
-
December 15, 2025Report on Large Holdings of Shares, etc. (General)
-
December 12, 2025Closure of Shareholder Register or Setting of Record Date
-
December 05, 2025Report on Large Holdings of Shares, etc. (General)
-
December 03, 2025Investor Relations (IR) Meeting
-
November 26, 2025Investor Relations (IR) Meeting
-
November 25, 2025Report on Large Holdings of Shares, etc. (General)
-
November 24, 2025Investor Relations (IR) Meeting
-
November 14, 2025Quarterly Report (2025.09)
-
November 10, 2025[Correction] Report on Large Holdings of Shares, etc. (General)
-
November 07, 2025Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
November 07, 2025Report on Ownership of Specified Securities, etc. by Executives and Major Shareholders
-
October 15, 2025Report on Results of Treasury Share Disposal
-
October 10, 2025Results of Securities Issuance (Voluntary Disclosure)
-
October 02, 2025Material Facts Report (Decision to Dispose of Treasury Shares)
-
October 02, 2025Material Facts Report (Decision to Issue Exchangeable Bonds)
-
October 01, 2025[Correction] Material Business Matters Related to Investment Decisions (Decision on IND Application, etc.)
(Phase 1 IND Approval for VRN110755) -
September 23, 2025Report on Large Holdings of Shares, etc. (General)
-
September 18, 2025Material Business Matters Related to Investment Decisions (Exercise of Option on the VRN04 Program Research and Execution of Asset Purchase Agreement)
-
September 08, 2025[Correction] Report on Large Holdings of Shares, etc. (General)
-
September 02, 2025Report on Large Holdings of Shares, etc. (General)
-
August 20, 2025[Correction] Material Business Matters Related to Investment Decisions (IND Application)
(A Phase 1 Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NSCLC)) -
August 14, 2025Semi-Annual Report (2025.06)
-
July 04, 2025Results of Securities Issuance (Voluntary Disclosure)
-
June 30, 2025Material Facts Report (Decision to Issue Convertible Bonds)
-
June 12, 2025Investor Relations (IR) Meeting
-
May 21, 2025Investor Relations (IR) Meeting
-
May 16, 2025Investor Relations (IR) Meeting
-
May 14, 2025[Correction] Material Business Matters Related to Investment Decisions (IND Application)
(A Phase 1 Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NSCLC)) -
May 09, 2025Quarterly Report (2025.03)
-
May 08, 2025Investor Relations (IR) Meeting
-
March 28, 2025Results of Annual General Meeting of Shareholders
-
March 28, 2025Report on Large Holdings of Shares, etc. (General)
-
March 28, 2025Report on Grant of Stock Options
-
March 28, 2025Report on Grant of Stock Options
-
March 28, 2025Report on Appointment, Dismissal, or Mid-Term Resignation of Outside Directors
-
March 25, 2025[Correction] Material Business Matters Related to Investment Decisions (Decision on IND Application, etc.)
(Phase 1 IND Approval for VRN101099) -
March 20, 2025Submission of Audit Report
-
March 20, 2025Annual Report (2024.12)
-
March 13, 2025Reference Documents for Proxy Solicitation
-
March 13, 2025Notice of Convening General Meeting of Shareholders
-
March 12, 2025Report on Reasons for Holding General Meeting of Shareholders on a Peak Date
-
March 12, 2025Resolution to Convene General Meeting of Shareholders
-
February 25, 2025Investor Relations (IR) Meeting
-
February 07, 2025Investor Relations (IR) Meeting
-
December 23, 2024Material Business Matters Related to Investment Decisions (Decision on IND Application, etc.)
(Phase 1 IND Approval for VRN101099) -
December 13, 2024Closure of Shareholder Register or Setting of Record Date
-
November 29, 2024[Correction] Material Business Matters Related to Investment Decisions (IND Application)
(A Phase 1 Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Efficacy of VRN101099 in Patients with HER2-Positive Solid Tumors) -
November 19, 2024Material Business Matters Related to Investment Decisions (IND Application)
(Phase 1 IND Application for VRN101099) -
November 14, 2024Quarterly Report (2024.09)
-
October 07, 2024[Correction] Exercise of Stock Options